Victoza/ Saxenda (Liarglutide)

Victoza/Saxenda (Liraglutide 6mg/3ml) is an FDA-approved injectable medication used for the treatment of Type 2 Diabetes Mellitus. It helps control blood sugar levels, promotes weight management, and reduces the risk of cardiovascular diseases in diabetic patients. Manufactured by Novo Nordisk, Victoza belongs to the GLP-1 receptor agonist class of drugs.

Key Benefits:

✅ Regulates Blood Sugar Levels – Stimulates insulin release in response to high blood sugar.
✅ Weight Management – Helps with appetite control and weight loss in diabetic patients.
✅ Reduces Cardiovascular Risks – Lowers the risk of heart attack and stroke in diabetes patients.
✅ Once-Daily Injection – Easy-to-use pen for convenient administration.

How It Works:

Victoza mimics the natural GLP-1 hormone, which regulates insulin production and slows down digestion. This leads to better glucose control and reduced hunger, aiding in both diabetes management and weight control.

Dosage & Administration:

🔹 Starting Dose: 0.6 mg once daily for the first week
🔹 Maintenance Dose: 1.2 mg or 1.8 mg once daily, as prescribed by a doctor
🔹 Injection Site: Subcutaneous (under the skin) – abdomen, thigh, or upper arm

Who Can Use Victoza?

✅ Adults & children (10+ years) with Type 2 Diabetes
✅ Those needing better blood sugar control despite diet & exercise
✅ Patients at risk of cardiovascular complications

Who Should Avoid Victoza?

🚫 Patients with Type 1 Diabetes or diabetic ketoacidosis
🚫 Those with a history of thyroid cancer or pancreatitis
🚫 Pregnant or breastfeeding women (consult a doctor)

Possible Side Effects:

⚠️ Nausea, vomiting, diarrhea
⚠️ Low blood sugar (if taken with insulin or sulfonylureas)
⚠️ Headache, dizziness, or fatigue.